Delivers real-time biopharma news and signals — powered by AI, curated for professionals.
Novo Nordisk's recent setback in the Alzheimer's disease (AD) space has sparked renewed interest in combination approaches, as industry experts and analysts see potential in pairing GLP-1 receptor agonists with other therapeutic modalities. The failure of semaglutide in the Phase III EVOKE program, while disappointing, has not dampened enthusiasm for exploring GLP-1's role in neurodegenerative diseases.
Biohaven Pharmaceuticals faced a significant setback as its drug candidate BHV-7000 failed to meet primary endpoints in a Phase 2 clinical trial for major depressive disorder (MDD). The announcement, made during the holiday period, has raised questions about the drug's future and its potential impact on the company's pipeline.
Elon Musk's neurotechnology company, Neuralink, is poised for a significant leap forward in 2026, with plans to dramatically scale up production of its brain-computer interface (BCI) devices and streamline the surgical implantation process. This development marks a crucial milestone in the company's mission to restore autonomy to individuals with neurological conditions.
The pharmaceutical industry faced unexpected challenges as both Sanofi and Corcept Therapeutics received FDA rejections for their respective drug applications during the recent holiday period. These decisions have significant implications for the treatment landscape of multiple sclerosis (MS) and Cushing's syndrome.
French pharmaceutical giant Sanofi has agreed to acquire Dynavax Technologies for $2.2 billion, marking a significant expansion of its vaccine portfolio. The deal, announced on December 24, 2025, will see Sanofi pay $15.50 per Dynavax share in cash, with the transaction expected to close in the first quarter of 2026.
New York City's healthcare landscape is set for a significant transformation as NYC Health + Hospitals, the largest municipal health care system in the nation, announces plans to merge with Brooklyn-based Maimonides Health. The merger, supported by a substantial $2.2 billion state grant, aims to bolster safety net healthcare in Brooklyn and expand access to high-quality care across the city.
Omeros Corporation has achieved a significant milestone with the U.S. Food and Drug Administration's (FDA) approval of Yartemlea (narsoplimab), marking the company's first-ever FDA nod in its 31-year history. The approval, announced on Christmas Eve, positions Yartemlea as the first treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in patients aged 2 and older.
The U.S. Food and Drug Administration (FDA) has approved Novo Nordisk's oral version of Wegovy for weight management, marking a significant milestone in the treatment of obesity and overweight individuals. This approval sets the stage for an intensified battle in the rapidly expanding GLP-1 drug market, with Eli Lilly's rival medication expected to follow closely behind.
Neurocrine Biosciences faced a setback in its clinical pipeline as its drug valbenazine failed to meet primary and key secondary endpoints in a Phase III trial for dyskinetic cerebral palsy (DCP). Despite this disappointment, the company's commercial performance remains strong, with its focus shifting to existing products and new opportunities in the obesity market.
Pharmaceutical giant Pfizer has disclosed a patient death in a long-term follow-up clinical trial of its recently approved hemophilia therapy, Hympavzi. The incident has prompted a thorough investigation and raised questions about the drug's safety profile.
In a flurry of late-year dealmaking, two biotechnology companies have made significant moves to reshape their businesses and advance key programs. Windtree Therapeutics continues its pivot away from drug development, while Vaccinex secures funding through an unconventional arrangement to push forward its Alzheimer's disease candidate.
Edwards Lifesciences has received Food and Drug Administration (FDA) approval for its Sapien M3 mitral valve replacement system, marking a significant advancement in the treatment of mitral regurgitation. This approval represents the first of its kind for a transcatheter therapy using a transseptal approach in the United States.
